CN1466467A - 提高妇女睾酮和相关类固醇浓度的方法 - Google Patents
提高妇女睾酮和相关类固醇浓度的方法 Download PDFInfo
- Publication number
- CN1466467A CN1466467A CNA018164331A CN01816433A CN1466467A CN 1466467 A CN1466467 A CN 1466467A CN A018164331 A CNA018164331 A CN A018164331A CN 01816433 A CN01816433 A CN 01816433A CN 1466467 A CN1466467 A CN 1466467A
- Authority
- CN
- China
- Prior art keywords
- testosterone
- women
- treatment
- acid
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
Abstract
Description
激素 | 均值±标准差 | 中位数 | 范围 |
睾酮(nmol/L) | 1.20±0.69 | 0.98 | 0.4-2.7 |
游离睾酮(pmol/L) | 12.80±5.59 | 12.53 | 4.1-24.2 |
总睾酮的游离睾酮百分比 | 1.4±1.1 | 1.1 | 0.4-6.3 |
促***(IU/L) | 7.2±3.3 | 6.7 | 3.0-18.7 |
***(IU/L) | 4.7±3.6 | 4.2 | 1.5-21.4 |
性激素结合球蛋白(nmol/L) | 66.1±22.7 | 71.0 | 17.8-114.0 |
表2:各种睾酮制剂的应用方式和剂量 | ||
制剂 | 应用途径 | 完全替代剂量 |
临床应用庚酸睾酮γ-环戊丙酸睾酮十一酸睾酮透皮睾酮贴剂透皮睾酮贴剂透皮睾酮植入物 | 肌肉注射肌肉注射口服阴囊皮肤非阴囊皮肤植在腹部皮肤下 | 200-25.0g/2-3周200mg/2周2-4粒40mg胶囊/天1贴/天1或2个***/天3-6个200mg植入物/6个月 |
开发中环糊精睾酮十一酸睾酮buciclate睾酮睾酮微球 | 舌下肌肉注射肌肉注射肌肉注射 | 2.5-5.0mg,每天2次1000mg/8-10周1000mg/12-16周315mg,11周 |
废弃17α-甲基睾酮氟*** | 口服舌下口服 | 25-5.0g/天10-25mg/天10-20mg/天 |
物质 | 每100g凝胶中的量(w/w) |
睾酮 | 1.0g |
Carbopol980 | 0.90g |
十四酸异丙酯 | 0.50g |
0.1N NaOH | 4.72g |
乙醇(95%w/w) | 72.5g* |
净化水(qsf) | 100g |
剂量(μL)(克) | Cavg均值(ng/dL) | 每天传送率(μg/天)a |
5.0 | 555(±225) | 3330 |
7.5 | 601(±309) | 3606 |
10.0 | 713(±209) | 4278 |
总睾酮 | 生物可利用的睾酮 | |
全身 | 0.22 | 0.22 |
侧棘 | 0.27 | 0.29 |
近端股骨 | 0.25 | 0.30 |
桡骨 | 0.27 | 0.28 |
表6:ESTRAGEL的组成 | |
物质 | 每100g凝胶的量(w/w) |
17-β-*** | 0.06g |
Carbopol980 | 1.0g |
三乙醇胺 | 1.35g |
乙醇(95%w/w) | (59ml) |
净化水(qsf) | 100g |
物质 | 量(w/w)/100g凝胶 |
睾酮 | 1.0g(或约0.5g) |
17-β-*** | 0.06g(或约0.10g) |
Carbopol980 | 1.0g |
三乙醇胺 | 1.35g |
十四酸异丙酯 | 0.50g |
0.1N NaOH | 4.72g |
乙醇(95%w/w) | 72.5g |
净化水(qsf) | 100g |
Claims (7)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/651,777 | 2000-08-30 | ||
US09/651,777 US6503894B1 (en) | 2000-08-30 | 2000-08-30 | Pharmaceutical composition and method for treating hypogonadism |
US70375300A | 2000-11-01 | 2000-11-01 | |
US09/703,753 | 2000-11-01 | ||
US29239801P | 2001-05-21 | 2001-05-21 | |
US60/292,398 | 2001-05-21 | ||
PCT/US2001/027199 WO2002017967A1 (en) | 2000-08-30 | 2001-08-29 | Method of increasing testosterone and related steroid concentrations in women |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2006100066288A Division CN101081203B (zh) | 2000-08-30 | 2001-08-29 | 水醇凝胶的制药用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1466467A true CN1466467A (zh) | 2004-01-07 |
CN100349572C CN100349572C (zh) | 2007-11-21 |
Family
ID=27404127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB018164331A Expired - Lifetime CN100349572C (zh) | 2000-08-30 | 2001-08-29 | 提高妇女睾酮和相关类固醇浓度的方法 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1322336B1 (zh) |
JP (1) | JP2004507511A (zh) |
KR (1) | KR20030048021A (zh) |
CN (1) | CN100349572C (zh) |
AU (2) | AU2001285367B2 (zh) |
BR (1) | BR0113649A (zh) |
CA (1) | CA2419573C (zh) |
DK (1) | DK1322336T3 (zh) |
ES (1) | ES2423899T3 (zh) |
HK (2) | HK1061804A1 (zh) |
IL (2) | IL154693A0 (zh) |
MX (1) | MXPA03001859A (zh) |
NO (1) | NO334991B1 (zh) |
NZ (1) | NZ536633A (zh) |
PL (1) | PL360992A1 (zh) |
PT (1) | PT1322336E (zh) |
WO (1) | WO2002017967A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN814496A0 (en) | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US20030027804A1 (en) * | 2001-06-27 | 2003-02-06 | Van Der Hoop Roland Gerritsen | Therapeutic combinations for the treatment of hormone deficiencies |
OA12856A (en) * | 2002-03-15 | 2006-09-15 | Unimed Pharmaceuticals Inc | Androgen pharmaceutical composition and method for treating depression. |
AU2003228314C1 (en) * | 2002-03-15 | 2009-03-26 | Besins Healthcare Luxembourg Sarl | Androgen pharmaceutical composition and method for treating depression |
MY139721A (en) * | 2002-04-19 | 2009-10-30 | Cpex Pharmaceuticals Inc | Pharmaceutical composition |
KR20050045946A (ko) | 2002-06-25 | 2005-05-17 | 애크럭스 디디에스 피티와이 리미티드 | 비정질 약학적 조성물을 이용한 경피전달속도의 제어 |
AUPS317302A0 (en) * | 2002-06-25 | 2002-07-18 | Drug Delivery Solutions Pty Ltd | Metastable pharmaceutical compositions |
AU2003240299B2 (en) * | 2002-06-25 | 2008-01-31 | Acrux Dds Pty. Ltd. | Metastable pharmaceutical compositions |
US20040259852A1 (en) * | 2003-06-18 | 2004-12-23 | White Hillary D. | Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome |
US8883769B2 (en) | 2003-06-18 | 2014-11-11 | White Mountain Pharma, Inc. | Methods for the treatment of fibromyalgia and chronic fatigue syndrome |
BRPI0414551B8 (pt) | 2003-10-10 | 2021-05-25 | Antares Pharma Ipl Ag | formulação farmacêutica transdérmica ou transmucosa e método de protelação ou inibição da cristalização de um agente ativo |
GB0409498D0 (en) * | 2004-04-28 | 2004-06-02 | Hunter Fleming Ltd | Transdermal steroid formulation |
CA2604400A1 (en) * | 2005-04-12 | 2006-10-19 | Unimed Pharmaceuticals, Inc. | Method of treating or preventing bone deterioration or osteoporosis |
KR20080016552A (ko) * | 2005-04-13 | 2008-02-21 | 유니메드 파마슈티칼스, 인크. | 여성의 테스토스테론 및 관련된 스테로이드의 농도를증가시키는 방법 |
WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
MX2007015255A (es) * | 2005-06-03 | 2008-02-22 | Acrux Dds Pty Ltd | Metodo y composicion para administracion transdermica de un farmaco. |
NZ563946A (en) | 2005-06-03 | 2012-02-24 | Acrux Dds Pty Ltd | Testosterone containing non-occlusive transdermal drug delivery composition for application to the arm pit / axilla |
GEP20125432B (en) | 2005-10-12 | 2012-03-26 | Unimed Pharmaceuticals Llc | Improved testosterone gel and use thereof |
CN101426475A (zh) | 2006-04-21 | 2009-05-06 | 安塔雷斯制药Ipl股份公司 | 使用用于经皮或经粘膜应用的制剂治疗热潮红的方法 |
EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
US8757912B2 (en) | 2009-12-23 | 2014-06-24 | Colgate-Palmolive Company | Oral care system, kit and method |
US9138046B2 (en) | 2009-12-23 | 2015-09-22 | Colgate-Palmolive Company | Oral care system, kit and method |
US8851779B2 (en) | 2009-12-23 | 2014-10-07 | Colgate-Palmolive Company | Oral care system, kit and method |
CN104287434B (zh) | 2009-12-23 | 2016-08-24 | 高露洁-棕榄公司 | 口腔护理*** |
EP2640398A4 (en) | 2010-11-18 | 2014-05-14 | White Mountain Pharma Inc | METHODS FOR TREATING CHRONIC OR REFRACTORY PAIN AND / OR INCREASING PAIN THRESHOLD IN A SUBJECT, AND ASSOCIATED PHARMACEUTICAL COMPOSITIONS |
EP3817731A4 (en) * | 2018-07-05 | 2022-04-06 | Celista Pharmaceuticals Llc | TRANSDERMAL TESTOSTERONE AND ESTRADIOL SPRAY |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4496556A (en) * | 1982-08-16 | 1985-01-29 | Norman Orentreich | Topical applications for preventing dry skin |
US5152997A (en) * | 1990-12-11 | 1992-10-06 | Theratech, Inc. | Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels |
US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
AU5855794A (en) * | 1993-01-19 | 1994-08-15 | Endorecherche Inc. | Therapeutic uses and delivery systems of dehydroepiandrosterone |
US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
AU6265998A (en) * | 1997-02-07 | 1998-08-26 | Theratech, Inc. | Composition and method for supplementing testosterone in women with symptoms of testosterone deficiency |
US5968919A (en) * | 1997-10-16 | 1999-10-19 | Macrochem Corporation | Hormone replacement therapy drug formulations for topical application to the skin |
US6319913B1 (en) * | 1997-11-10 | 2001-11-20 | Cellegy Pharmaceuticals, Inc. | Penetration enhancing and irritation reducing systems |
-
2001
- 2001-08-29 IL IL15469301A patent/IL154693A0/xx unknown
- 2001-08-29 DK DK01964525.8T patent/DK1322336T3/da active
- 2001-08-29 AU AU2001285367A patent/AU2001285367B2/en not_active Expired
- 2001-08-29 NZ NZ536633A patent/NZ536633A/xx not_active IP Right Cessation
- 2001-08-29 EP EP01964525.8A patent/EP1322336B1/en not_active Expired - Lifetime
- 2001-08-29 AU AU8536701A patent/AU8536701A/xx active Pending
- 2001-08-29 WO PCT/US2001/027199 patent/WO2002017967A1/en active Application Filing
- 2001-08-29 MX MXPA03001859A patent/MXPA03001859A/es active IP Right Grant
- 2001-08-29 PL PL01360992A patent/PL360992A1/xx not_active Application Discontinuation
- 2001-08-29 BR BR0113649-6A patent/BR0113649A/pt not_active Application Discontinuation
- 2001-08-29 CA CA002419573A patent/CA2419573C/en not_active Expired - Lifetime
- 2001-08-29 KR KR10-2003-7003111A patent/KR20030048021A/ko active Search and Examination
- 2001-08-29 CN CNB018164331A patent/CN100349572C/zh not_active Expired - Lifetime
- 2001-08-29 JP JP2002522940A patent/JP2004507511A/ja active Pending
- 2001-08-29 ES ES01964525T patent/ES2423899T3/es not_active Expired - Lifetime
- 2001-08-29 PT PT1964525T patent/PT1322336E/pt unknown
-
2003
- 2003-02-28 IL IL154693A patent/IL154693A/en active IP Right Grant
- 2003-02-28 NO NO20030954A patent/NO334991B1/no not_active IP Right Cessation
-
2004
- 2004-07-06 HK HK04104842A patent/HK1061804A1/xx not_active IP Right Cessation
-
2008
- 2008-05-30 HK HK08106037.4A patent/HK1115537A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO334991B1 (no) | 2014-08-18 |
ES2423899T3 (es) | 2013-09-25 |
MXPA03001859A (es) | 2004-05-21 |
WO2002017967A1 (en) | 2002-03-07 |
IL154693A (en) | 2010-04-15 |
NO20030954D0 (no) | 2003-02-28 |
DK1322336T3 (da) | 2013-07-15 |
KR20030048021A (ko) | 2003-06-18 |
EP1322336A1 (en) | 2003-07-02 |
PT1322336E (pt) | 2013-08-05 |
CA2419573C (en) | 2007-04-03 |
AU2001285367B2 (en) | 2006-05-18 |
IL154693A0 (en) | 2003-09-17 |
HK1061804A1 (en) | 2004-10-08 |
CN100349572C (zh) | 2007-11-21 |
NZ536633A (en) | 2006-03-31 |
HK1115537A1 (en) | 2008-12-05 |
PL360992A1 (en) | 2004-09-20 |
EP1322336B1 (en) | 2013-07-03 |
NO20030954L (no) | 2003-04-28 |
JP2004507511A (ja) | 2004-03-11 |
AU8536701A (en) | 2002-03-13 |
BR0113649A (pt) | 2004-07-20 |
CA2419573A1 (en) | 2002-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101081203B (zh) | 水醇凝胶的制药用途 | |
CN100349572C (zh) | 提高妇女睾酮和相关类固醇浓度的方法 | |
US20150250801A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
US20030022877A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
EP2283865A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
US20050049233A1 (en) | Method for treating erectile dysfunction and increasing libido in men | |
AU2001285367A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
JP2008536851A (ja) | 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法 | |
US20110306582A1 (en) | Androgen pharmaceutical composition and method for treating depression | |
JP2005515964A (ja) | ホルモン欠乏症を治療するための治療用組成物 | |
CA2484164C (en) | Androgen pharmaceutical composition and method for treating depression | |
RU2286787C2 (ru) | Способ повышения концентрации тестостерона и родственных стероидов у женщин |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1061804 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1061804 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: UNIMED PHARMACEUTICALS INC.; BESANY LABS INTERNAT Free format text: FORMER OWNER: UNIMED PHARMACEUTICALS INC. Effective date: 20081010 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081010 Address after: Illinois, USA Co-patentee after: Bezany Laboratories International GmbH Patentee after: Yu Ni maid pharmaceutical company Address before: Illinois Patentee before: Unimaid Pharmacetical Inc. |
|
C56 | Change in the name or address of the patentee |
Owner name: UNIMED PHARMACEUTICALS INC. Free format text: FORMER NAME: UNIMAID PHARMACETICAL INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Illinois Co-patentee after: Bezany Laboratories International GmbH Patentee after: Unimed Pharmaceutical Co., Ltd. Address before: Illinois Co-patentee before: Bezany Laboratories International GmbH Patentee before: Unimaid Pharmacetical Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: BEIZANYI HEALTH CARE LUXEMBOURG CO., LTD. Free format text: FORMER OWNER: LABORATOIRES BESINS INTERNATIONAL S.A.S. Effective date: 20140318 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140318 Address after: Georgia Patentee after: Unimed Pharmaceutical Co., Ltd. Patentee after: Bezany healthcare Luxemburg Ltd Address before: Illinois Patentee before: Unimed Pharmaceutical Co., Ltd. Patentee before: Bezany Laboratories International GmbH |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20071121 |